GlassScriptPhysician profile
Carrie Daigle
NPI 1477758571
$1,181.93
in general payments reported to CMS, 2019-2025
16 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.35 · 2021: $26.15 · 2022: $220 · 2023: $533 · 2024: $257 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $923.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $694.76 | 2021-2025 | Vraylar, Ubrelvy, Botox |
| Bayer Healthcare Pharmaceuticals INC. | $94.92 | 2023 | |
| Pfizer INC. | $59.10 | 2023-2024 | |
| Exact Sciences Corporation | $51.77 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $39.29 | 2023-2025 | Mounjaro, Kisunla |
| Amgen INC. | $32.81 | 2023 | Repatha, Otezla |
| Inspire Medical Systems, INC. | $32.36 | 2025 | Inspire |
| Novo Nordisk INC | $31.47 | 2023-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.73 | 2024-2025 | Jardiance |
| Dexcom, INC. | $18.98 | 2023 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $18.20 | 2023 | Quviviq |
| Impel Pharmaceuticals INC. | $17.56 | 2023 | Trudhesa |
| Glaxosmithkline, LLC. | $16.37 | 2025 | Arexvy, Shingrix, Bexsero |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.24 | 2023 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $15.02 | 2023 | Farxiga |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $12.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Daigle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.